PARP2 and cancer: Therefore, it has been hypothesized that selectively inhibiting PARP1 would reduce PARPi toxicity associated with PARP2 inhibition while improving synthetic lethality in HRD cancers and subsequently improving the efficacy of PARPi treatments.